Abstract Title:

Benefits of Bifidobacterium Animalis Subsp Lactis Probiotic in Experimental Periodontitis.

Abstract Source:

J Periodontol. 2016 Sep 23:1-20. Epub 2016 Sep 23. PMID: 27660886

Abstract Author(s):

Luiz F F Oliveira, Sérgio L Salvador, Pedro H F Silva, Flávia A C Furlaneto, Luciene Figueiredo, Renato Casarin, Edilson Ervolino, Daniela B Palioto, Sérgio L S Souza, Mario Taba, Arthur B Novaes, Michel R Messora

Article Affiliation:

Luiz F F Oliveira


BACKGROUND: This study evaluated the effects of topical administration of probiotic bacteria (PROB) of the genus Bifidobacterium on experimental periodontitis (EP) in rats.

METHODS: 32 rats were divided into groups C (control; without EP), EP (EP only), C-HN019 (control+PROB) and EP-HN019 (EP+PROB). On day 0 of the experiment, animals of groups EP and EP-HN019 received cotton ligatures around mandibular first molars (MFM). In groups C-HN019 and EP-HN019, 1mL of suspensions containing Bifidobacterium animalis subsp lactis (B. lactis) HN019 was topically administered in the subgingival region of MFM on days 0, 3 and 7. In groups C and EP, topical administrations were performed using a sham suspension (without PROB). All animals were euthanized at day 14. Gingival tissue, hemi-mandibles and oral biofilm were collected. Data were statistically analyzed (P<0.05).

RESULTS: Group EP presented greater bone porosity, trabecular separation and connective tissue attachment loss as well as reduced bone volume than all the other groups (P<0.05). In group EP-HN019, there were greater proportions of Actinomyces and Streptococcus-like species and lower proportions of Veillonella parvula, Capnocytophaga sputigena, Eikenella corrodens, Prevotella intermedia-like species than group EP. Besides, group EP-HN019 presented greater expressions of Osteoprotegerin (OPG) and beta-defensins than group EP (P<0.05). Group EP presented greater levels of Interleukin (IL)-1β and Receptor Activator of Nuclear Factor-Kappa B ligand (RANKL) than group EP-HN019 (P<0.05).

CONCLUSION: Topical use of B. lactis HN019 promotes a protective effect against alveolar bone and connective tissue attachment losses attributable to EP in rats, modifying immunoinflammatory and microbiological parameters.

Study Type : Animal Study

Print Options

Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2021 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.